Preventing chlamydia comes down to a combination of barrier protection during sex, regular screening, and prompt treatment if you or a partner tests positive. With over 1.5 million cases reported in the U.S. in 2024 alone, chlamydia remains the most commonly reported bacterial sexually transmitted infection in the country. The good news: it’s also one of the most preventable.
How Condoms Reduce Your Risk
Consistent condom use is the most accessible and well-studied way to lower your chances of getting chlamydia. A study published in the American Journal of Epidemiology found that people who used condoms consistently had a 58% lower rate of chlamydia and gonorrhea compared to those who didn’t, after adjusting for other risk factors. That’s a significant reduction, but it’s not 100%, which is why condoms work best as one layer of protection rather than the only one.
The key word is “consistent.” Using condoms sometimes offers far less protection than using them every time. In the same study, infection rates among consistent condom users were 30%, compared to 43% among those exposed to an infected partner without consistent use. Latex and polyurethane condoms are effective against chlamydia because the bacteria spread through bodily fluids, and a physical barrier blocks that exchange.
Protection During Oral and Anal Sex
Chlamydia doesn’t only infect the genitals. It can also establish itself in the throat and rectum, and these infections often cause no symptoms at all. If you’re having oral sex, dental dams (thin sheets of latex or polyurethane placed between the mouth and the vulva or anus) act as a barrier against fluid exchange. For oral sex performed on a penis, a standard condom serves the same purpose.
Anal sex carries a particularly high transmission risk because the rectal lining is thin and vulnerable to infection. Condoms during anal sex are important for prevention, and if you’re a man who has sex with men, screening at the site of contact (rectum, urethra, or throat) catches infections that a standard urine test would miss entirely.
Screening Catches What Prevention Misses
Because chlamydia is frequently silent, with the majority of infections causing no symptoms, routine screening is one of the most effective prevention tools available. You can’t avoid spreading an infection you don’t know you have, and you can’t get treated for one either. Screening breaks the chain.
The CDC recommends annual chlamydia screening for all sexually active women under 25. Women 25 and older should also be screened annually if they have risk factors: a new partner, more than one partner, a partner who has other partners, inconsistent condom use outside a mutually monogamous relationship, or a previous STI.
For heterosexual men at low risk, the evidence doesn’t strongly support routine screening, though it may be offered in high-prevalence settings like STI clinics or correctional facilities. Men who have sex with men should be screened at least once a year at all sites of sexual contact, regardless of condom use. If you’re on PrEP, living with HIV, or you or your partners have multiple partners, screening every 3 to 6 months is recommended.
When To Get Tested After Exposure
If you think you’ve been exposed, timing matters. Chlamydia tests (typically a urine sample or swab) can detect infection as early as one week after exposure in most cases. Waiting two weeks catches nearly all infections. Testing too early can produce a false negative, leaving you with a misleading sense of security.
Partner Treatment Prevents Reinfection
One of the most overlooked parts of chlamydia prevention is what happens after a positive test. Getting treated yourself is only half the equation. If your sexual partner isn’t also treated, you’re likely to get reinfected the next time you have sex with them. The CDC recommends retesting about three months after treatment for exactly this reason.
Expedited partner therapy, where your healthcare provider gives you a prescription or medication to deliver directly to your partner without requiring them to come in for their own visit, reduces reinfection by 29% compared to simply telling your partner to go see a doctor. This approach is legal in most U.S. states and removes a common barrier: the reality that many partners never follow through on a referral.
Notifying partners can feel uncomfortable, but it’s one of the single most effective things you can do to protect both yourself and others. Many health departments also offer anonymous notification services that contact your partners on your behalf.
Doxycycline After Exposure
A newer prevention strategy involves taking the antibiotic doxycycline within 72 hours after unprotected sex, sometimes called doxy-PEP (post-exposure prophylaxis). This approach has shown striking results in clinical trials, particularly among men who have sex with men.
In a French trial, taking doxycycline after exposure reduced chlamydia infections by 70%. A second French trial found an even larger effect, with an 89% reduction in chlamydia. Results in a Kenyan trial among cisgender women were less conclusive, with a 27% reduction that wasn’t statistically significant, so the strategy appears more proven for certain populations right now.
Doxy-PEP isn’t a blanket recommendation for everyone. It’s generally discussed as an option for men who have sex with men and transgender women who are at high risk for bacterial STIs. There are legitimate concerns about antibiotic resistance with widespread use, so this is something to discuss with a healthcare provider if you think it fits your situation.
Mutual Monogamy and Fewer Partners
The math is straightforward: fewer sexual partners means fewer opportunities for exposure. Being in a mutually monogamous relationship where both partners have tested negative is one of the most reliable ways to avoid chlamydia. The “mutually” part is critical, and so is the testing. Assumptions about a partner’s status aren’t protective; confirmed test results are.
Reducing your number of concurrent partners also lowers risk. Sexual networks where multiple people have overlapping partners create conditions where a single infection can spread rapidly, often before anyone develops symptoms or gets tested.
No Vaccine Yet, but One Is in Development
Unlike HPV or hepatitis B, there is no vaccine for chlamydia. But that may change within the next several years. A vaccine called CTH522 has completed early-stage human trials and was found to be safe, generating both antibodies and immune responses in the genital and ocular tracts. Sanofi is also developing an mRNA-based chlamydia vaccine that entered clinical trials in March 2025, with results expected by January 2028.
These are still years away from being available to the public, if they prove effective. For now, prevention relies entirely on the strategies above: barriers, screening, prompt treatment, and honest communication with partners.